Cancer vaccine research has suffered clinical-stage setbacks over the years, but there have been suggestions that combining them with checkpoint inhibitors and other new anticancers has promise. That's cause enough for Germany's mRNA-focused biotech CureVac AG to attract its second big pharma collaborator, Eli Lilly & Co., for its immunotherapy research.
Other potential reasons include the backing of SAP software company founder Dietmar Hopp and the Bill & Melinda Gates Foundation, which have both invested in Tubingen-based CureVac, and a line-up of other collaborators that include Boehringer Ingelheim GMBH, with which
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?